OS Therapies (NYSE:OSTX) (NYSE: OSTX) is a clinical-stage biotechnology company dedicated to developing innovative cancer immunotherapies through the localized delivery of therapeutic genes. The company’s proprietary platform combines electroporation technology with plasmid DNA constructs to stimulate anti-tumor immune responses directly within solid tumors. Headquartered in San Diego, California, OS Therapies focuses on creating treatments that harness the body’s own immune system to target and eliminate malignant cells.
The cornerstone of OS Therapies’ pipeline is its ImmunoPulse® IL-12 program, which delivers interleukin-12 encoding plasmids into tumors via a minimally invasive electroporation device. This approach has been evaluated across multiple tumor types, including non-small cell lung cancer, melanoma, pancreatic cancer, and head and neck cancers. Preclinical studies and early-stage clinical trials have demonstrated encouraging signs of tumor regression, immune cell activation, and manageable safety profiles, supporting further development in combination with established immuno-oncology agents.
Founded in 2008, OS Therapies has built a strong foundation in gene therapy and electroporation expertise. Over the years, the company has collaborated with leading academic institutions and clinical research centers to refine its delivery technology and expand its therapeutic applications. In addition to its U.S. operations, OS Therapies is advancing partnerships in Europe and Asia to facilitate multi-regional trials and regulatory submissions, reflecting its commitment to bringing novel treatments to patients worldwide.
OS Therapies is led by a management team and board of directors with extensive experience in biotech innovation, clinical development, and regulatory strategy. The company continues to invest in research and development to broaden its pipeline, enhance product candidates, and explore new indications. Through its focus on precision delivery and immunomodulation, OS Therapies aims to establish a new standard of care for patients with hard-to-treat solid tumors.
